Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Olaparib (Primary) ; Carboplatin; Paclitaxel
- Indications Ovarian cancer; Uterine cancer
- Focus Adverse reactions
- 25 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 25 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
- 20 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.